It can be not possible to ascertain whether or not these gatherings are relevant on to the use of PDE5 inhibitors, on the affected individual's fundamental vascular chance components or anatomical defects, to a mix of these variables, or to other components [see WARNINGS AND Safeguards and Individual Information and facts].A starting dose of 25 mg